Organon & Co. (NYSE:OGN) Now Covered by Citigroup

Equities researchers at Citigroup initiated coverage on shares of Organon & Co. (NYSE:OGN) in a research report issued on Thursday, Briefing.com reports. The firm set a “buy” rating and a $35.00 price target on the stock. Citigroup’s target price suggests a potential upside of 14.90% from the stock’s previous close.

Several other analysts also recently commented on the company. Cowen started coverage on Organon & Co. in a research note on Thursday, June 3rd. They set a “market perform” rating and a $40.00 price objective for the company. Evercore ISI assumed coverage on Organon & Co. in a research report on Thursday, June 10th. They set an “outperform” rating on the stock. JPMorgan Chase & Co. assumed coverage on Organon & Co. in a research report on Tuesday, June 15th. They set a “neutral” rating and a $38.00 target price on the stock. Morgan Stanley assumed coverage on Organon & Co. in a research report on Friday, June 11th. They set an “equal weight” rating and a $33.00 target price on the stock. Finally, Truist assumed coverage on Organon & Co. in a research report on Wednesday, June 2nd. They set a “buy” rating and a $48.00 target price on the stock. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $38.17.

Organon & Co. stock opened at $30.46 on Thursday. Organon & Co. has a fifty-two week low of $27.25 and a fifty-two week high of $38.75.

Organon & Co. (NYSE:OGN) last posted its earnings results on Sunday, June 20th. The company reported $1.58 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.52 by $0.06.

Several institutional investors have recently modified their holdings of the business. Pflug Koory LLC purchased a new position in shares of Organon & Co. during the 2nd quarter worth $63,000. First PREMIER Bank purchased a new position in shares of Organon & Co. in the 2nd quarter worth $85,000. Vaughan Nelson Investment Management L.P. purchased a new position in shares of Organon & Co. in the 2nd quarter worth $107,000. Gradient Investments LLC purchased a new position in shares of Organon & Co. in the 2nd quarter worth $115,000. Finally, Cardinal Capital Management purchased a new position in shares of Organon & Co. in the 2nd quarter worth $204,000.

About Organon & Co.

Organon & Co, a science-based pharmaceutical company, develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive.

Featured Story: Commodities

Analyst Recommendations for Organon & Co. (NYSE:OGN)

Receive News & Ratings for Organon & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organon & Co. and related companies with MarketBeat.com's FREE daily email newsletter.